Utility of PTEN, MLH1, ARID1A And ?-Catenin, Biomarkers In Endometrial Hyperplasia and Endometrioid Endometrial Carcinoma

Abstract

Objective: Endometrial carcinomas are divided into two groupsroughly:Endometrioid (Type I) and NVon-endometrioid (TypeII). The majority of the endometrial carcinomas are of endometrioidtype and, this type of carcinoma is associated withhyperplasia which is formed due to unopposed estrogen.Inthis study, our purpose is to reveal the expression status of thePTEN, MLH1, ARID1A and ?-catenin, biomarkers in all typesof endometrial hyperplasia (EH) and endometrioid endometrialcarcinoma (EC).Material and Methods: We conducted a retrospective studywith 202 cases including 82 EC cases, 71 simple EH caseswithout atypia, 16 complex EH cases without atypia, 9 simpleatypical EH cases, 24 complex atypical EH cases which werediagnosed at Istanbul Civilization University Göztepe Trainingand Research Hospital. 10 normal endometrial tissues wereused for the purpose of control.Results: In our study, loss of PTEN ratio was 61%, loss of ARID1Aratio was 52,4%, loss of MLH1 ratio was 40,2% in patientswith EC. These ratios were 87,5%, 41,7%, 20,8%, respectivelyin patients with atypical complex EH and 12,7%; 4,2%;1,4% in patients with simple EH without atypia.Conclusion: In the light of these findings it has been demonstratedthat PTEN, ARID1A and MLH1 have a role in the transitionfrom simple EH to atypical complex EH, and also MLH1has a role in the transition from aytpical complex EH to EC